NEO – neogenomics, inc. (US:NASDAQ)
Stock Stats
News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead [Yahoo! Finance]
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics (NASDAQ:NEO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
NeoGenomics (NASDAQ:NEO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Form 4 NEOGENOMICS INC For: Feb 21 Filed by: Olivo Alicia C
Form 4 NEOGENOMICS INC For: Feb 21 Filed by: Stone Warren
Form 4 NEOGENOMICS INC For: Feb 21 Filed by: Sherman Jeffrey Scott
Form 4 NEOGENOMICS INC For: Feb 21 Filed by: Aunan Greg D
Form 10-K NEOGENOMICS INC For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.